

Personalized Medicine

Part I: Scientific & Commercial Aspects

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

June 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written "The Textbook of Gene Therapy", which is the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version of it is incorporated in the 2013 edition of Gene Therapy published by Jain PharmaBiotech. The most recent books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed April 2017), "Textbook of Personalized Medicine" (Springer 2009, Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2018, in preparation), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been interested in using biotechnology to develop personalized medicine since 1997. He has also lectured and conducted several workshops on personalized medicine worldwide.

A B O U T T H I S R E P O R T

Prof. Jain wrote the first report on Personalized Medicine in 1998, which was published by Decision Resources Inc, USA. The second edition was published in 2001 by Informa Publications, London. Since 2003, the report is published and continuously updated and rewritten at Jain PharmaBiotech.

**June 2018 (first edition published in 1998 by Decision Resources Inc)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	26
1. Basic Aspects.....	28
Definition of personalized medicine.....	28
History of medical concepts relevant to personalized medicine	29
Ayurveda as a personalized healthcare system	31
Personalized aspects of ancient oriental systems of medicine	31
Evolution of modern personalized medicine	31
Molecular biological basis of personalized medicine	32
The human genome	32
<i>ENCODE</i>	32
Chromosomes	33
Genes.....	33
<i>The genetic code</i>	34
<i>Gene expression</i>	34
<i>DNA sequences and structure</i>	34
Genetic variations in the human genome	35
<i>Single nucleotide polymorphisms</i>	35
<i>Copy number variations in the human genome</i>	36
<i>Insertions and deletions in the human genome</i>	37
<i>Large scale variation in human genome</i>	38
<i>Structural variations in the human genome</i>	39
<i>Mapping and sequencing of structural variation from human genomes</i>	39
<i>1000 Genomes Project</i>	40
<i>Role of DNA sequencing in the development of personalized medicine</i>	41
<i>Human Variome Project</i>	42
<i>Interconnected genetic and genomic patterns in human diseases</i>	42
Mitochondrial tRNA and personalized medicine.....	43
Molecular alterations in disease	43
Basics technologies for developing personalized medicine	44
Definitions of technologies relevant to personalized medicine	44
Problems with the ICH definitions of pharmacogenomics and pharmacogenetics	44
'Omics' and personalized medicine	45
Relationship of various technologies to personalized medicine	45
Conventional medicine versus personalized medicine	45
Personalized medicine and evidence-based medicine	46
Role of genetics in future approaches to healthcare	46
Genetic disease	46
Human disease and genes.....	47
Genetic and environmental interactions in etiology of human diseases.....	47
Role of genetics in development of personalized medicines	48
<i>Genetic databases</i>	48
<i>Clinical Genomic Database</i>	48
<i>Genetic epidemiology</i>	49
<i>Limitations of medical genetics</i>	49
Role of epigenetics in personalized medicine	50
Role of systems biology in personalized medicine	50
Systems pharmacology.....	51
Systems medicine.....	52
Synthetic biology and development of personalized medicines.....	53
Role of bioelectronics in development of personalized medicine	54
A personalized approach to environmental factors in disease.....	54
Reclassification of diseases	55
Translational science and personalized medicine.....	56
Personalization of multimodal therapies.....	56
2. Molecular Diagnostics in Personalized Medicine	58
Introduction	58
Molecular diagnostic technologies	58
PCR-based methods	59
<i>DirectLinear™ Analysis</i>	59
<i>Denaturing high-performance liquid chromatography</i>	60
<i>Multiplex Allele-Specific Diagnostic Assay</i>	60
<i>Representational oligonucleotide microarray analysis</i>	60
<i>Restriction fragment length polymorphism (RFLP)</i>	60
<i>Real-time PCR for detection of CNVs</i>	61
Non-PCR methods.....	61
<i>Arrayed primer extension (APEX)</i>	61

<i>Enzymatic Mutation Detection (EMD)</i>	61
DNA sequencing	61
<i>Sanger-sequencing technology</i>	62
<i>ABI PRISM® 310 Genetic Analyzer</i>	63
<i>High-throughput paired end transcriptome sequencing</i>	63
Emerging sequencing technologies.....	63
<i>4300 DNA analyzer</i>	64
<i>Apollo 100</i>	64
<i>Cyclic array sequencing</i>	65
<i>CEQ™ 8000</i>	65
<i>DeepCAGE sequencing</i>	65
<i>Electron microscope-based DNA sequencing</i>	65
<i>Genometrica™ sequencer</i>	66
<i>GS-FLEX system (Roche/454)</i>	66
<i>IBS sequencing technology</i>	67
<i>Illumina's sequencing technology</i>	68
<i>MegaBACE 500</i>	69
<i>Microdroplet-based PCR for large-scale targeted sequencing</i>	69
<i>Multiplex amplification of human DNA sequences</i>	69
<i>Nanoscale sequencing</i>	70
<i>Next generation sequencing based on Lightning Terminators</i>	70
<i>Polonator sequencer</i>	70
<i>RainStorm™ microdroplet technology</i>	71
<i>Sequential DEXAS</i>	71
<i>SOLiD technology</i>	72
<i>Sequencing by hybridization</i>	73
<i>Whole genome sequencing</i>	73
<i>Bioinformatic tools for analysis of genomic sequencing data</i>	74
<i>Clinical Genomicist Workspace for managing NGS-based clinical tests</i>	74
<i>Detection of single molecules in real time</i>	74
<i>Direct observation of nucleotide incorporation</i>	74
<i>Molecular Combing</i>	75
<i>Nanopore sequencing</i>	75
<i>DNA sequence by use of nanoparticles</i>	75
<i>Zero-mode waveguide nanostructure arrays</i>	75
<i>Future prospects of sequencing</i>	76
<i>Role of DNA sequencing in development of personalized medicine</i>	76
<i>Role of RNA sequencing in development of personalized medicine</i>	78
Biochips and microarrays	78
Role of biochip/microarray technology in personalized medicine.....	79
Applications of biochip/microarray technology in personalized medicine	80
Standardizing the microarrays	81
Biochip technologies.....	81
<i>GeneChip</i>	81
<i>AmpliChip CYP450</i>	82
Microfluidics	83
<i>Lab-on-a-chip</i>	84
<i>Micronics' microfluidic technology</i>	84
<i>LabCD</i>	84
<i>Microfluidic automated DNA analysis using PCR</i>	84
<i>Integrated microfluidic bioassay chip</i>	85
Electronic detection of nucleic acids on microarrays.....	85
Strand displacement amplification on a biochip	86
Rolling circle amplification on DNA microarrays.....	86
Universal DNA microarray combining PCR and ligase detection reaction	86
Protein biochips	86
<i>ProteinChip</i>	87
<i>LabChip for protein analysis</i>	88
<i>TRINECTIN proteome chip</i>	88
<i>Protein expression microarrays</i>	88
<i>Microfluidic devices for proteomics-based diagnostics</i>	89
<i>New developments in protein biochips/microarrays</i>	89
<i>Protein biochips/microarrays for personalized medicine</i>	90
SNP genotyping	90
Genotyping and haplotyping.....	91
<i>Haplotype Specific Extraction</i>	92
<i>Computation of haplotypes</i>	92
<i>HapMap project</i>	92
<i>Haplotyping for whole genome sequencing</i>	93
<i>Predicting drug response with HapMap</i>	95
<i>Companies developing haplotyping technology</i>	95

Technologies for SNP analysis.....	95
Biochip and microarray-based detection of SNPs	96
<i>SNP genotyping by MassARRAY.....</i>	96
<i>BeadArray technology.....</i>	96
<i>SNP-IT primer-extension technology</i>	97
<i>Use of NanoChip for detection of SNPs.....</i>	97
Electrochemical DNA probes	97
Laboratory Multiple Analyte Profile	97
PCR-CTPP (confronting two-pair primers)	98
TaqMan real-time PCR	98
Locked nucleic acid	99
Molecular inversion probe based assays	99
Pyrosequencing	99
Smart amplification process version 2	100
Zinc finger proteins	100
Mitochondrial SNPs.....	100
Limitations of SNP in genetic testing.....	101
Concluding remarks on SNP genotyping	101
Companies involved in developing technologies/products for SNP analysis	101
Impact of SNPs on personalized medicine	103
Detection of copy number variations	103
CNVer algorithm for CNV detection.....	103
CNVnator for discovery of CNVs and genotyping	104
Study of rare variants in pinpointing disease-causing genes	104
Optical Mapping	105
Proteomics in molecular diagnosis.....	105
Proteomic strategies for biomarker identification.....	106
<i>Proteomic technologies for detection of biomarkers in body fluids</i>	<i>106</i>
Protein patterns.....	106
Layered Gene Scanning	107
Comparison of proteomic and genomic approaches in personalized medicine	107
Role of nanobiotechnology in molecular diagnostics.....	108
Cantilevers for personalized medical diagnostics	108
Role of biomarkers in personalized medicine.....	109
Role of biosensors in personalized medicine.....	111
Biomarkers for diagnostics	112
Biomarkers for drug development	112
Gene expression profiling	112
DNA microarrays.....	113
Analysis of single-cell gene expression.....	113
Gene expression profiling based on alternative RNA splicing	114
Whole genome expression array	115
Tangerine™ expression profiling	115
Gene expression analysis on biopsy samples	116
Profiling gene expression patterns of white blood cells.....	116
Serial analysis of gene expression (SAGE).....	116
Multiplexed Molecular Profiling	117
Gene expression analysis using competitive PCR and MALDI TOF MS	117
Companies involved in gene expression analysis	118
Monitoring in vivo gene expression by molecular imaging	119
Molecular imaging and personalized medicine.....	119
Combination of diagnostics and therapeutics	119
Use of molecular diagnostics for stratification in clinical trials	120
Companion diagnostics	120
Companies involved in companion diagnostics	121
Point-of-care diagnosis.....	123
Companies developing point-of-care diagnostic technologies	124
Point-of-care diagnosis of infections	126
Advantages versus disadvantages of point-of-care diagnosis	126
Future prospects of point-of-care diagnosis	127
Genetic testing for disease predisposition	127
Preventive genetics by early diagnosis of mitochondrial diseases	128
Direct-to-consumer genetic services.....	128
Role of diagnostics in integrated healthcare	129
Concept of integrated healthcare	129
Components of integrated healthcare	130
<i>Screening</i>	<i>130</i>
<i>Disease prediction.....</i>	<i>130</i>
<i>Early diagnosis</i>	<i>130</i>
<i>Prevention</i>	<i>131</i>
<i>Therapy based on molecular diagnosis.....</i>	<i>131</i>

Monitoring of therapy	131
Advantages and limitations of integrated healthcare.....	131
Commercially available systems for integrated healthcare.....	132
Future of molecular diagnostics in personalized medicine	132

3. Pharmacogenetics	134
Basics of pharmacogenetics.....	134
Role of molecular diagnostics in pharmacogenetics.....	135
Role of pharmacogenetics in pharmaceutical industry.....	136
Study of the drug metabolism and pharmacological effects	136
Causes of variations in drug metabolism	136
Enzymes relevant to drug metabolism	137
Pharmacogenetics of phase I metabolism.....	137
CYP450.....	137
P450 CYP 2D6 inhibition by selective serotonin reuptake inhibitors.....	139
Cytochrome P450 polymorphisms and response to clopidogrel.....	140
Lansoprazole and cytochrome P450.....	140
Glucose-6-phosphate dehydrogenase	140
Pharmacogenetics of phase II metabolism.....	141
N-Acetyltransferase.....	141
Uridine diphosphate-glucuronosyltransferase.....	142
Measurement of CYP isoforms	142
Polymorphism of drug transporters	143
Genetic variation in drug targets.....	143
Polymorphisms of kinase genes	144
Effect of genetic polymorphisms on disease response to drugs	144
Ethnic differences in drug metabolism	145
Gender differences in pharmacogenetics	145
Role of pharmacogenetics in drug safety	146
Adverse drug reactions	146
Adverse drug reactions in children	147
Adverse drug reactions related to toxicity of chemotherapy.....	147
Genetically determined adverse drug reactions.....	147
Malignant hyperthermia	149
Pharmacogenetics of clozapine-induced agranulocytosis.....	149
Role of pharmacogenetics in warfarin therapy.....	150
Role of pharmacogenetics in antiplatelet therapy	151
Role of pharmacogenetics in carbamazepine therapy.....	152
Role of pharmacogenetics in statin therapy	152
FDA consortium linking genetic biomarkers to serious adverse events	153
Therapeutic drug monitoring, phenotyping, and genotyping	154
Therapeutic drug monitoring	154
Phenotyping	155
Genotyping	156
Genotyping vs phenotyping.....	156
Phenomics	157
Limitations of genotype-phenotype association studies	157
Molecular toxicology in relation to personalized medicines.....	157
Toxicogenomics	158
Biomarkers of drug toxicity	158
Drug-induced mitochondrial toxicity	158
Companies involved in molecular toxicology.....	159
Gene expression studies	159
Pharmacogenetics in clinical trials	160
Postmarketing pharmacogenetics.....	160
Clinical implications of pharmacogenetics	161
Application of CYP450 genotyping in clinical practice	161
Genotype-based drug dose adjustment.....	161
Pharmacogenomic biomarker information in drug labels.....	161
Standardized terminology for clinical pharmacogenetic test results.....	165
Use of pharmacogenetics in clinical pharmacology.....	165
Application of CYP2C19 pharmacogenetics for personalized medicine.....	165
Genotyping for identifying responders to sulfasalazine.....	165
HLA alleles associated with lumiracoxib-related liver injury	166
Pharmacogenetic basis of thiopurine toxicity	166
Tranilast-induced hyperbilirubinemia due to gene polymorphism.....	167
Linking pharmacogenetics with pharmacovigilance	167
Genetic susceptibility to ADRs.....	167
Linking genetic testing to postmarketing ADR surveillance	167
Recommendations for the clinical use of pharmacogenetics	168
Limitations of pharmacogenetics	168

Pharmacoepiggenomics vs pharmacogenetics in drug safety	169
Future role of pharmacogenetics in personalized medicine	169
4. Pharmacogenomics.....	170
Introduction	170
Basics of pharmacogenomics	171
Pharmacogenomics and drug discovery	171
<i>Preclinical prediction of drug efficacy</i>	<i>173</i>
Pharmacogenomics and clinical trials	173
Impact of genetic profiling on clinical studies.....	174
Limitations of the pharmacogenomic-based clinical trials.....	175
Pharmacogenomic aspects of major therapeutic areas	176
Oncogenomics	176
<i>Oncogenes</i>	<i>176</i>
<i>Tumor suppressor genes.....</i>	<i>177</i>
Cardiogenomics	178
Neuropharmacogenomics.....	180
<i>Pharmacogenomics of Alzheimer's disease</i>	<i>180</i>
<i>Pharmacogenomics of depression.....</i>	<i>181</i>
<i>Pharmacogenomics of bipolar disorder.....</i>	<i>181</i>
<i>Pharmacogenomics of schizophrenia.....</i>	<i>182</i>
<i>Companies involved in neurogenomics-based drug discovery.....</i>	<i>183</i>
Current status and future prospects of pharmacogenomics	183
5. Role of Pharmacoproteomics	186
Basics of proteomics.....	186
Proteomic approaches to the study of pathophysiology of diseases	186
Single cell proteomics for personalized medicine	187
Diseases due to misfolding of proteins	187
<i>Therapies for protein misfolding.....</i>	<i>188</i>
Significance of mitochondrial proteome in human disease	188
Proteomic technologies for drug discovery and development	189
Proteins and drug action	189
Role of reverse-phase protein microarray in drug discovery.....	189
Role of proteomics in clinical drug safety.....	189
Toxicoproteomics	190
Applications of pharmacoproteomics in personalized medicine	191
6. Role of Metabolomics in Personalized Medicine	192
Metabolomics and metabonomics	192
Metabolomics bridges the gap between genotype and phenotype	192
Metabolomics, biomarkers and personalized medicine	193
Metabolomic technologies	193
Urinary profiling by capillary electrophoresis.....	194
Lipid profiling	194
Role of metabolomics in biomarker identification and pattern recognition.....	195
Pharmacometabonomics.....	195
Metabonomic technologies for toxicology studies.....	196
Metabonomics/metabolomics and personalized nutrition.....	197
Metabolomics for personalized medicine	197
7. Personalized Biological Therapies.....	198
Introduction	198
Recombinant human proteins	198
Therapeutic monoclonal antibodies	198
Cell therapy	199
Autologous tissue and cell transplants	199
Stem cells.....	199
<i>iPSCs for personalized cell therapy</i>	<i>199</i>
<i>Role of stem cells derived from unfertilized embryos</i>	<i>200</i>
Cloning and personalized cell therapy.....	200
Use of stem cells for drug testing	200
Gene therapy	200
Gene editing by CRISPR/Cas9 system.....	201
Personalized gene therapy for cancer	201
<i>Stem cell-based personalized gene therapy for cancer.....</i>	<i>202</i>
Personalized vaccines	202
Personalized vaccines for viral diseases	202
Personalized cancer vaccines	202
Antisense therapy	202

RNA interference.....	203
MicroRNAs	204
8. Personalized Non-pharmacological Therapies.....	206
Introduction	206
Acupuncture	206
Personalized acupuncture therapy.....	206
Personalized hyperbaric oxygen therapy	207
Personalized nutrition.....	207
Nutrigenomics	208
<i>Evolutionary basis of nutrigenomics</i>	<i>209</i>
<i>Genomics of vitamin D and calcium supplementation.....</i>	<i>209</i>
<i>Nutrigenomics and functional foods</i>	<i>210</i>
<i>Nutrigenomics and personalized medicine</i>	<i>210</i>
<i>Nutriproteomics</i>	<i>210</i>
Nutrigenetics and personalized medicine.....	211
Personalized diet prescription	211
<i>Personalized nutrition and aging</i>	<i>212</i>
<i>Personalized diet for diabetics.....</i>	<i>213</i>
Role of systems medicine in personalized nutrition.....	213
Companies involved in personalized nutrition	213
Personalized physical exercise	213
Variations in response to aerobic exercise	214
Variations in exercise-induced muscle hypertrophy and strength.....	214
Personalized surgery	214
9. Personalized Medicine in Major Therapeutic Areas	216
Introduction	216
Personalized management of infections	217
Genetic susceptibility to infections.....	217
Management of HIV	217
<i>CD4 counts as a guide to drug therapy for AIDS</i>	<i>217</i>
<i>Drug-resistance in HIV</i>	<i>217</i>
<i>Genetics of human susceptibility to HIV infection</i>	<i>219</i>
<i>Measurement of Replication Capacity.....</i>	<i>219</i>
<i>Personalized vaccine for HIV.....</i>	<i>220</i>
<i>Prevention of adverse reactions to antiviral drugs</i>	<i>220</i>
<i>Pharmacogenetics and HIV drug safety.....</i>	<i>221</i>
<i>Pharmacogenomics of antiretroviral agents</i>	<i>221</i>
<i>Role of diagnostic testing in management of HIV</i>	<i>221</i>
<i>Role of genetic variations in susceptibility to HIV-1</i>	<i>222</i>
<i>Role of personalized HIV therapy in controlling drug resistance.....</i>	<i>222</i>
<i>PhenoSense® to test HIV drug resistance.....</i>	<i>223</i>
<i>Sequencing for detecting mutations to personalize HIV therapy</i>	<i>223</i>
Personalized treatment of hepatitis B	224
Personalized treatment of hepatitis C	224
<i>Responders vs non-responders to treatment for hepatitis C.....</i>	<i>225</i>
<i>Drug resistance in hepatitis C.....</i>	<i>226</i>
<i>Challenges for personalized management of hepatitis C.....</i>	<i>226</i>
Personalized management of tuberculosis	226
Personalized management of fungal infections.....	227
Psychiatric disorders	227
Psychopharmacogenetics/psychopharmacodynamics	228
<i>Serotonin genes.....</i>	<i>228</i>
<i>Calcium channel gene.....</i>	<i>228</i>
<i>Dopamine receptor genes</i>	<i>229</i>
<i>COMT genotype and response to amphetamine.....</i>	<i>229</i>
<i>Methylenetetrahydrofolate reductase</i>	<i>229</i>
<i>Genetic loci associated with risk of major depressive disorder.....</i>	<i>229</i>
<i>Role of gene mutations in ADHD</i>	<i>230</i>
<i>Genotype and response to methylphenidate in children with ADHD</i>	<i>230</i>
<i>GeneSight tests for individualized therapy of psychiatric disorders</i>	<i>230</i>
Personalized antipsychotic therapy.....	231
Personalized antidepressant therapy	233
<i>Biomarkers of response to antidepressant treatment</i>	<i>234</i>
<i>EEG to predict adverse effects and evaluate antidepressant efficacy.....</i>	<i>234</i>
<i>GeneSight pharmacogenomic test</i>	<i>235</i>
<i>Individualization of SSRI treatment</i>	<i>235</i>
<i>Role of protein sFRP3 in predicting response to antidepressants.....</i>	<i>237</i>
<i>Treatment resistant depression.....</i>	<i>237</i>
<i>Vilazodone with a test for personalized treatment of depression.....</i>	<i>237</i>

Neurological disorders	238
Introduction to personalized neurology	238
Personalized management of Alzheimer's disease	238
Personalized management of Parkinson's disease.....	240
<i>Brain imaging for diagnosis of neurodegenerative parkinsonism.....</i>	240
<i>Direct-to-consumer genetic testing in PD.....</i>	240
<i>Discovery of subgroup-selective drug targets in PD.....</i>	241
<i>Personalized cell therapy for PD.....</i>	241
<i>Pharmacogenetics of PD.....</i>	242
<i>Use of wearable sensors to monitor PD response to levodopa therapy.....</i>	242
Personalized management of amyotrophic lateral sclerosis.....	242
Personalized management of epilepsy	243
<i>Adverse effects of AEDs.....</i>	243
<i>An algorithm for personalized management of epilepsy.....</i>	243
<i>Biomarkers of epilepsy.....</i>	244
<i>Drug resistance in epilepsy.....</i>	246
<i>Genetics/genomics of epilepsy.....</i>	247
<i>Pharmacogenomics of epilepsy.....</i>	248
<i>Rasmussen's encephalitis.....</i>	249
<i>Selection of the right AED.....</i>	250
<i>Future of management of epilepsy.....</i>	250
Personalized management of migraine.....	251
<i>Individualization of use of triptans for migraine.....</i>	251
<i>Multitarget therapeutics for personalized treatment of headache.....</i>	251
<i>Personalized strategy for prevention of migraine attacks.....</i>	252
Personalized management of intracranial aneurysms.....	253
<i>Personalized management of cerebral vasospasm following SAH.....</i>	253
Personalized management of stroke	253
<i>Anticoagulation for stroke prevention.....</i>	255
<i>Application of proteomics for personalizing stroke management.....</i>	256
<i>Brain imaging for personalized management of stroke.....</i>	256
<i>Personalized management of intracerebral hemorrhage.....</i>	257
<i>Revascularization procedures in chronic post-stroke stage.....</i>	258
<i>Personalized cell therapy for management of stroke.....</i>	258
<i>Management of stroke according to stage.....</i>	258
Personalized treatment of multiple sclerosis	259
<i>Autologous bone marrow stem cell therapy for multiple sclerosis.....</i>	260
<i>Fusokine method of personalized cell therapy of multiple sclerosis.....</i>	260
<i>Immunopathological patterns of demyelination for assessing therapy.....</i>	260
<i>Personalizing mitoxantrone therapy of multiple sclerosis.....</i>	261
<i>Pharmacogenomics of IFN-β therapy in multiple sclerosis.....</i>	261
<i>Preclinical detection of multiple sclerosis in children.....</i>	263
<i>Predictive models of individual treatment response in MS.....</i>	263
<i>T cell-based personalized vaccine for MS.....</i>	263
<i>Targeting MS therapy to cell type of lesion.....</i>	264
Personalized management of traumatic brain injury	264
<i>Biomarkers of TBI.....</i>	264
<i>Comparative effectiveness research for management of TBI.....</i>	265
<i>CT scores for prognosis and risk stratification of TBI.....</i>	265
Personalized management of myasthenia gravis	265
Personalized management of pain.....	266
<i>Genetic factors in response to pain.....</i>	266
<i>Genetic mutations with loss of pain.....</i>	267
<i>Genetic mutations and painful conditions.....</i>	267
<i>Pharmacogenetics/pharmacogenomics of pain.....</i>	267
<i>Personalized management of pain with opioids.....</i>	268
<i>Pharmacogenetics of NSAIDs.....</i>	269
<i>Mechanism-specific management of pain.....</i>	270
<i>Preoperative testing to tailor postoperative analgesic requirements.....</i>	270
<i>Personalized analgesics.....</i>	270
<i>Signature of pain on brain imaging.....</i>	271
<i>Concluding remarks on personalized management of pain.....</i>	271
Personalized management of sleep disorders.....	272
<i>Personalized therapy of insomnia.....</i>	272
Future of personalized neurology	272
Personalized management of ophthalmic disorders.....	273
Proteomics-based personalized management of uveitis.....	273
Combining cell and gene therapies for retinal disorders	273
Cardiovascular disorders	274
Role of diagnostics in personalized management of cardiovascular disease.....	274
<i>Cardiovascular disorders with a genetic component.....</i>	274

<i>Gene mutations associated with risk of coronary heart disease</i>	275
<i>Gene variant as a risk factor for sudden cardiac death</i>	276
<i>KIF6 gene test as a guide to management of heart disease</i>	277
<i>NGS sequencing for management of cardiovascular disorders</i>	277
<i>Personalized antiplatelet therapy after PCI</i>	277
Assessing patients with coronary heart disease	278
Assessing coronary artery disease for percutaneous coronary interventions	279
Companion diagnostics for therapy of cardiovascular disorders	280
Biomarkers and personalized management of cardiovascular disorders	281
Pharmacogenomics of cardiovascular disorders	281
Nanotechnology-based personalized therapy of cardiovascular diseases	281
Personalized management of chronic myocardial ischemia	282
<i>Management of chronic angina pectoris</i>	282
Personalized management of myocardial infarction	283
Management of heart failure	283
<i>β-blockers</i>	283
<i>Bucindolol</i>	283
<i>BiDil</i>	284
Management of atrial fibrillation	284
Management of hypertension	286
<i>Adjusting therapy of hypertension to fluctuations of blood pressure</i>	287
<i>Choice of drugs for hypertension</i>	288
<i>Control of blood pressure with vagal nerve stimulation</i>	288
<i>Correction of causes and risk factors of hypertension</i>	289
<i>Genes and hypertension</i>	289
<i>Guideline for management of HPN</i>	289
<i>Improving management of HPN by targeting new pathways</i>	290
<i>Individualized therapy of HPN based on risk factors of heart disease</i>	291
<i>Personalized management of hypertensive patients with diabetes</i>	291
<i>Personalized management of hypertensive patients with albuminuria</i>	292
<i>Personalized management of hypertension in the elderly</i>	292
<i>Personalized management of hypertension in women</i>	293
<i>Pharmacogenomics of diuretic drugs</i>	293
<i>Pharmacogenomics of ACE inhibitors</i>	294
<i>Prediction of antihypertensive activity of rosfuroxin</i>	294
<i>Role of pharmacogenetics in management of hypertension</i>	295
<i>Scheme for management of hypertension by personalized approach</i>	295
Personalized lipid-lowering therapies	296
<i>NIR spectroscopy of plaques to guide cholesterol-lowering therapy</i>	296
<i>Polymorphisms in genes involved in cholesterol metabolism</i>	296
<i>Role of eNOS gene polymorphisms</i>	297
<i>Prediction of response to statins</i>	297
<i>Personalized management of women with hyperlipidemia</i>	298
<i>Therapeutic alternatives in patients with statin intolerance</i>	298
<i>Treatment of familial hypercholesterolemia</i>	299
<i>PCSK9 inhibitors</i>	299
Thrombotic disorders	300
<i>Factor V Leiden mutation</i>	300
<i>Anticoagulant therapy</i>	301
<i>Antiplatelet therapy</i>	302
Personalized management of aortic aneurysms	303
Clinical trials of personalized therapy of cardiovascular diseases	303
Project euHeart for personalized management of heart disease	304
Modification of life style factors in management of cardiovascular disorders	304
Multimorbidity in patients with cardiovascular disease	305
Systems biology approach to personalized cardiology	305
Concluding remarks on personalized management of cardiovascular diseases	305
Personalized management of pulmonary disorders	306
Role of genetic ancestry in lung function	306
Targeted drug delivery for personalized management of pulmonary disorders	306
Personalized therapy of asthma	307
<i>Asthma phenotyping for improving therapeutic precision</i>	307
<i>Biomarkers for predicting response to corticosteroid therapy</i>	307
<i>Genetic polymorphism and response to β₂-adrenergic agonists</i>	308
<i>Genotyping in asthma</i>	308
<i>IgE as guide to dosing of omalizumab for asthma</i>	309
<i>Lebrikizumab for personalised treatment of asthma</i>	309
Personalized management of chronic obstructive pulmonary disease	310
Personalized management of idiopathic pulmonary fibrosis	310
Personalized management of skin disorders	311
Genetic testing for personalized skin care	311

Management of hair loss based on genetic testing.....	312
Personalized urology	312
Personalized approaches in immunology	312
<i>Immunological tests in personalized medicine.....</i>	<i>313</i>
<i>Antibody profiles.....</i>	<i>313</i>
<i>Role of Mannose-binding lectin testing in personalized medicine</i>	<i>313</i>
Pharmacogenetics and pharmacogenomics of immunosuppressive agents	313
Personalized management of patients with lupus erythematosus.....	314
Personalized therapy of rheumatoid arthritis	315
Biomarkers and diagnostics for personalizing therapy of rheumatoid arthritis	315
DIATSTAT™ anti-cyclic citrullinated peptides in rheumatoid arthritis.....	316
Genetics and epigenetic aspects of rheumatoid arthritis.....	316
Personalization of COX-2 inhibitor therapy	316
Personalized biological therapy of RA.....	317
Personalization of infliximab therapy	317
Personalized therapy of RA guided by anti-citrullinated protein antibodies.....	317
Variations in the effectiveness of therapies for RA.....	318
Personalized management of obesity	318
Basics of obesity	318
Genetics of obesity as a basis for personalized management	319
Limitations of personalized approach to management of obesity	319
Personalized management of diabetes	320
<i>Biomarkers in the management of diabetes.....</i>	<i>320</i>
<i>Personalized management of monogenic diabetes.....</i>	<i>320</i>
<i>Selection from multiple options for treatment of T2DM</i>	<i>321</i>
<i>Stratification of diabetes into 5 subgroups and personalized medicine.....</i>	<i>321</i>
Management of genetic disorders	321
Personalized treatment of cystic fibrosis	322
Personalized management of Prader-Willi syndrome.....	323
Personalized management of gastrointestinal disorders	324
Role of microbiome in personalized management of gastrointestinal disorders.....	324
Personalized therapy of inflammatory bowel disease	324
Personalized management of lactose intolerance.....	325
Personalized approaches to improve organ transplantation	325
Personalization of kidney transplantation	326
<i>Cell-based bioengineered kidney transplant.....</i>	<i>326</i>
Personalization of cardiac transplantation.....	326
<i>Cell-based regeneration of heart for personalized transplantation.....</i>	<i>327</i>
Prediction of rejection for personalizing anti-rejection treatment.....	327
Personalized immunosuppressant therapy in organ transplants.....	328
Role of immunological biomarkers in monitoring grafted patients	329
Improved matching of blood transfusion	330
Personalized approaches to addiction.....	330
Reversal of cocaine-evoked synaptic plasticity	330
Pharmacogenetics of drug addiction	331
Genetic polymorphism and management of alcoholism	331
Personalized therapy for smoking cessation.....	332
<i>Antidepressant therapy for smoking cessation</i>	<i>332</i>
<i>Effectiveness of nicotine patches in relation to genotype</i>	<i>333</i>
Personalized geriatrics	333
Chronological vs biological age	333
Pharmacogenetics and adverse drug reactions.....	333
Systems pharmacology approach to disorders of aging	334
Personalized pediatrics.....	334
WGS for personalized management of genetic disorders in critically ill infants.....	334
Personalized nephrology.....	334
Personalized management of chronic kidney disease	334
<i>Genes and chronic kidney disease</i>	<i>334</i>
<i>MicroRNAs and chronic kidney disease.....</i>	<i>335</i>
<i>Metabolomics and chronic kidney disease.....</i>	<i>335</i>
<i>TGF-β1 as a target for therapy of chronic kidney disease</i>	<i>335</i>
<i>Proteomics and chronic kidney disease</i>	<i>336</i>
Personalized management of renal disease associated with hypertension.....	336
<i>ACE inhibitors as renoprotective agents in hypertension.....</i>	<i>336</i>
<i>Gene associated with end-stage renal disease and hypertension</i>	<i>336</i>
Personalized approach to type I primary hyperoxaluria	337
Personalized approaches to miscellaneous problems	337
Female sexual dysfunction	337
<i>Hormone replacement therapy in women.....</i>	<i>337</i>
Personalized treatment of malaria.....	338
Personalized management of osteoporosis	338

Personalized care of trauma patients	339
Personalized medical care of astronauts during space flights	339
Personalized management of motion sickness.....	340
Personalized treatment of rare diseases.....	340
Personalized management of DNA repair disorders	341
Personalized preventive medicine	341
10. Personalized Therapy of Cancer	342
Introduction	342
Challenges of cancer classification.....	342
Molecular biology of cancer as basis for personalized management	343
<i>Cancer epigenetics/epigenomics and personalized therapy</i>	<i>344</i>
<i>Cell division and mitotic spindles.....</i>	<i>344</i>
<i>Chromosomes and cancer</i>	<i>344</i>
<i>Chromosomal instability.....</i>	<i>345</i>
<i>DNA damage, repair and cancer.....</i>	<i>345</i>
<i>Gene mutations and cancer.....</i>	<i>346</i>
<i>Telomeres and cancer.....</i>	<i>347</i>
Systems biology of cancer.....	347
Relationships of technologies for personalized management of cancer	347
Impact of molecular diagnostics on the management of cancer	348
A universal NGS-based oncology test system	349
Analysis of RNA splicing events in cancer	349
Analysis of chromosomal alterations in cancer cells	350
Cancer classification using microarrays	350
Cancer gene panel for detection of genetic alterations	351
Companion diagnostics for cancer	351
Circulating tumor cells isolation and characterization	351
Circulating cell-free DNA for monitoring personalized cancer therapy.....	352
Detection of loss of heterozygosity	352
Diagnostics for detection of minimal residual disease.....	353
DNA repair biomarkers	353
DNA sequencing for prognosis of cutaneous T cell lymphoma	353
Fluorescent in situ hybridization.....	354
Gene expression profiling.....	354
<i>Gene expression profiling in hematological cancers</i>	<i>354</i>
<i>Gene expression profiling in prostate cancer.....</i>	<i>355</i>
<i>Gene expression profiles predict chromosomal instability in tumors.....</i>	<i>355</i>
<i>OncoMatch tumor genotyping.....</i>	<i>356</i>
<i>Synthetic dosage lethality predicts tumor growth and patient survival</i>	<i>356</i>
GPS Cancer test.....	356
Modulation of CYP450 activity for cancer therapy	356
NanoFlares for detection of CTCs	357
Pathway-based analysis of cancer	357
<i>Conversion of gene-level information into pathway-level information.....</i>	<i>357</i>
<i>Personalized therapies based on oncogenic pathways signatures.....</i>	<i>357</i>
Quantum dot-based test for DNA methylation.....	358
Role of molecular imaging in personalized therapy of cancer	358
<i>Functional diffusion MRI.....</i>	<i>359</i>
<i>FDG-PET/CT for personalizing cancer treatment.....</i>	<i>359</i>
<i>Image-guided personalized drug delivery in cancer</i>	<i>360</i>
<i>Optoacoustic imaging and nanoparticles in cancer management</i>	<i>360</i>
<i>Tumor imaging and elimination by targeted gallium corrole.....</i>	<i>360</i>
<i>Future prospects of molecular imaging in management of cancer.....</i>	<i>361</i>
Unraveling the genetic code of cancer	361
Cancer prognosis	361
Personalized cancer prevention	362
Detection of mutations for cancer risk assessment and prevention	363
Impact of biomarkers on management of cancer.....	363
HER-2/neu oncogene as a biomarker for cancer.....	363
L-asparaginase treatment of cancer guided by a biomarker.....	364
miRNA biomarkers for personalized management of cancer.....	364
Oncogene GOLPH3 as a cancer biomarker	364
Predictive biomarkers for efficacy of anticancer therapy	365
Sequencing to discover biomarkers to personalize cancer treatment.....	365
VeraTag™ assay system for cancer biomarkers.....	365
Determination of response to therapy	366
Biomarker-based assays for predicting response to anticancer therapeutics	366
Ex vivo testing of tumor biopsy for chemotherapy sensitivity	367
Genomic approaches to predict response to anticancer agents.....	367
<i>Gene expression patterns to predict response of cancer to therapy</i>	<i>367</i>

<i>Genomic analysis of tumor biopsies</i>	368
<i>Genotype-dependent efficacy of pathway inhibition in cancer</i>	368
<i>Mutation detection at molecular level</i>	368
<i>RNA Disruption Assay™</i>	369
<i>Role of genetic variations in susceptibility to anticancer drugs</i>	369
Non-genetic factors for variations in response of cancer cells to drugs	369
Profiling of cancer therapy in zebrafish xenografts to predict response.....	369
Proteomic analysis of tumor biopsies to predict response to treatment	370
Real-time apoptosis monitoring	370
Serum nucleosomes as indicators of sensitivity to chemotherapy	370
Targeted microbubbles to tumors for monitoring anticancer therapy.....	371
PET imaging for determining response to chemotherapy	371
<i>PET imaging with tyrosine kinase inhibitors</i>	372
Concluding remarks about predicting response to anticancer therapy	372
Molecular diagnostics combined with cancer therapeutics.....	372
Aptamers for combined diagnosis and therapeutics of cancer	373
Combining diagnosis and therapy of metastatic cancer	373
Detection and destruction of CTCs with nanoparticles and X-rays.....	374
Molecular profiling of cancer.....	374
Targeted cancer therapies	374
Targeting glycoproteins on cell surface	375
Targeting pathways in cancer	375
Targeted personalized anticancer medicines in clinical use	375
Immunotherapy of cancer	376
Monoclonal antibodies for personalized management of cancer	376
Targeted MAb-based immune therapy of cancer.....	377
<i>MAbs targeted to alpha fetaprotein receptor</i>	377
<i>MAbs targeted to tumor blood vessels</i>	378
<i>MAbs that selectively target cancer</i>	378
<i>Velociximab</i>	378
MAbs for immune activation	379
Functional MAb-based therapies.....	379
Immunotherapy of dormant cancer	380
Combined use of MAbs and cytokines	380
Combining diagnostics with therapeutics based on MAbs.....	381
<i>Radiolabeled antibodies for detection and targeted therapy of cancer</i>	381
Cancer immunotherapy based on suppression of enzymes	382
Personalized cancer vaccines.....	383
Antigen-specific vaccines	383
<i>Active immunotherapy based on antigen specific to the tumor</i>	383
Tumor-derived vaccines.....	384
<i>FANG vaccine</i>	385
<i>MyVax</i>	385
<i>OncoVAX</i>	385
<i>Tumor cells treated with dinitrophenyl</i>	385
<i>Prophage</i>	386
<i>Melacine</i>	386
Patient-specific cell-based vaccines	386
<i>Dendritic cell-based vaccines</i>	386
Adoptive cell therapy.....	388
<i>Combination of antiangiogenic agents with ACT</i>	390
<i>Genetically targeted T cells for treating B cell malignancies</i>	390
<i>Genetic engineering of tumor cells</i>	390
<i>Hybrid cell vaccination</i>	391
Personalized peptide cancer vaccines.....	391
Targeting core mutations in cancer	391
Current status and future prospects of personalized cancer vaccines	392
Personalized radiation therapy	393
Peptide receptor radionuclide therapy.....	394
Use of radiation sensitivity biomarkers to personalized radiotherapy	394
Use of imaging to monitor radioimmunotherapy of non-Hodgkin lymphoma.....	395
Role of nanobiotechnology in personalized management of cancer	395
Design of future personalized cancer therapies	396
Personalized therapy of cancer based on cancer stem cells.....	396
Role of CRISPR-Cas9 in personalized cancer gene therapy	397
Role of epigenetics in development of personalized cancer therapies	397
<i>Cancer epigenetics and immunotherapy</i>	398
Selective destruction of cancer cells while sparing normal cells	398
<i>Sphingolipids</i>	399
<i>Hyperbaric oxygen as adjunct to radiotherapy</i>	399
<i>Targeting response to transformation-induced oxidative stress</i>	399

<i>Targeting enzymes to prevent proliferation of cancer cells</i>	400
Tissue systems biology approach to personalized management of cancer.....	400
Role of oncoproteomics in personalized therapy of cancer	400
Cancer tissue proteomics	400
Proteomics technologies to guide targeted drug selection for cancer.....	401
<i>LC-MS/MS proteomics as a companion diagnostic</i>	401
<i>Personalized cancer therapy based on targeted proteomics</i>	402
Role of metabolomics in personalized therapy of cancer	403
Role of sequencing in personalized therapy of cancer	404
Pharmacogenomic-based chemotherapy	405
Whole genome technology to predict drug resistance	405
Anticancer drug selection based on molecular characteristics of tumor.....	405
Testing microsatellite-instability for response to chemotherapy.....	405
Pharmacogenetics of cancer chemotherapy	406
CYP 1A2	407
Thiopurine methyltransferase	407
Dihydropyrimidine dehydrogenase	407
UGT1A1 test as guide to irinotecan therapy.....	408
Role of computational models in personalized anticancer therapy	408
A computational model of kinetically tailored treatment	408
Mathematical modeling of tumor microenvironments.....	409
Modeling signaling pathways to reposition anticancer drugs	409
Therapy resistance in cancer	410
Mechanism of therapy resistance in cancer.....	410
<i>Cancer stem cells and radioresistance</i>	410
<i>Expression of P-glycoprotein gene by tumor</i>	411
<i>Overexpression of multidrug resistance gene</i>	411
<i>P53 mutations</i>	411
<i>Role of splice variants in resistance to cancer therapy</i>	411
Detection of drug resistance.....	412
<i>Anaplastic lymphoma kinase</i>	412
<i>CRISPR for studying mechanism of drug-resistance in cancer</i>	412
<i>Metabolic profiling of cancer</i>	412
Management of drug resistance in cancer	413
<i>Chemogenomic approach to drug resistance</i>	413
<i>Determination of chemotherapy response by topoisomerase levels</i>	413
<i>Management of drug resistance in leukemia</i>	413
<i>Patient-derived xenograft mouse models in drug resistant cancer</i>	414
<i>Resistance to vaccines in cancer recurrence after surgery</i>	415
<i>Systems biology approach to drug-resistant cancer</i>	415
Personalized therapy of cancer metastases	415
Technologies for analysis of CTCs.....	415
<i>Microfluidic technologies</i>	416
<i>BEAMing technology for analysis of circulating tumor DNA</i>	416
<i>Technologies for detection of interplay of environments and CTCs</i>	417
Systemic antitumor effect of localized radiotherapy for cancer metastases	417
Diagnosis of cancer of an unknown primary.....	418
Personalized management of cancers of various organs/systems	418
Personalized management of bladder tumors	418
Personalized management of brain tumors.....	419
<i>Aptamers for selective targeting of tumor initiating cells in GBM</i>	419
<i>Bioinformatic approach to personalizing treatment of GBM</i>	419
<i>Biosimulation approach to personalizing treatment of brain cancer</i>	420
<i>Brain cancer chip for personalized drug screening</i>	420
<i>Combination of gene therapy and CAR-T cell therapy for GBM</i>	420
<i>Drug resistance in GBM</i>	421
<i>Genetics and genomics of GBM</i>	421
<i>Genomic analysis as a guide to personalized therapy of GBM</i>	423
<i>Induced neural stem cells for personalized therapy of GBM</i>	423
<i>Molecular diagnostics for personalized management of GBM</i>	424
<i>Personalized vaccine for GBM</i>	426
<i>Personalized chemotherapy of GBM</i>	426
<i>Personalized therapy of oligodendroglial tumors</i>	427
<i>Personalized therapy of neuroblastomas</i>	428
<i>Personalized therapy of medulloblastomas</i>	429
<i>Personalized management of germ cell brain tumors</i>	429
<i>Personalized management of meningiomas</i>	429
<i>Supratentorial hemispheric diffuse low-grade gliomas</i>	430
<i>Targeted therapy of BRAF V600E mutant papillary craniopharyngioma</i>	430
<i>Future prospects of personalized therapy of malignant brain tumors</i>	431
Personalized management of breast cancer	431

<i>Biomarker-guided decisions for breast cancer therapy</i>	431
<i>Developing personalized drugs for breast cancer</i>	432
<i>Gene expression plus conventional predictors of breast cancer</i>	432
<i>Her2 testing in breast cancer as a guide to treatment</i>	433
<i>HER2/neu-derived peptide vaccine for breast cancer</i>	435
<i>Prediction of cell signaling pathways from gene expression patterns</i>	435
<i>Trends in treatment patterns and outcomes for DCIS</i>	436
<i>Molecular diagnostics in breast cancer</i>	436
<i>Molecular classification of infiltrating breast cancer</i>	439
<i>Monitoring of circulating tumor cells in breast cancer</i>	439
<i>Pharmacogenetics of breast cancer</i>	440
<i>Proteomics-based personalized management of breast cancer</i>	440
<i>Predicting response to chemotherapy in breast cancer</i>	440
<i>Prediction of resistance to chemotherapy in breast cancer</i>	444
<i>Prediction of adverse reaction to radiotherapy in breast cancer</i>	444
<i>Prediction of recurrence in breast cancer for personalizing therapy</i>	445
<i>Prognostic tests for breast cancer</i>	446
<i>Racial factors in the management of breast cancer</i>	449
<i>RATHER consortium to study personalized approach to breast cancer</i>	449
<i>Ribociclib as first-line therapy for HR-positive breast cancer</i>	450
<i>TAILORx (Trial Assigning Individualized Options for Treatment)</i>	450
<i>Tamoxifen therapy for ER-positive breast cancer</i>	450
<i>Triple negative breast cancer</i>	450
<i>Treatment resistance in hormone receptor-positive breast cancer</i>	451
<i>Current trends and future of breast cancer research</i>	452
<i>Understanding tumor diversity in mouse mammary cancer model</i>	453
Personalized management of ovarian cancer	453
<i>Early diagnosis of ovarian cancer</i>	454
<i>Determining response to chemotherapy in ovarian cancer</i>	454
<i>Prognosis of ovarian cancer based on CLOVAR</i>	455
<i>Recurrent and drug-resistant ovarian cancer</i>	455
<i>Pathway targeted therapies for ovarian cancer</i>	457
<i>Repurposing auranofin for treatment of ovarian cancer</i>	458
<i>Subtype-specific therapies for epithelial ovarian cancer</i>	458
<i>Targeting hematogenous metastasis of ovarian cancer</i>	458
<i>Vynfinit® for platinum-resistant ovarian cancer</i>	459
Personalized management of head and neck cancer	459
<i>Molecular characterization of head and neck cancer using omics</i>	459
<i>Relevance of biomarkers of HPV-related head and neck cancer</i>	459
<i>Molecular targeted therapies for HNSCC</i>	460
Personalized management of hematological malignancies	460
<i>B cell malignancies</i>	461
<i>Personalized management of acute lymphoblastic leukemia</i>	461
<i>Personalized management of chronic lymphocytic leukemia</i>	462
<i>Personalized management of acute myeloid leukemia</i>	465
<i>Personalized management of chronic myeloid leukemia</i>	467
<i>Personalized management of multiple myeloma</i>	467
<i>Personalized management of myelodysplastic syndrome</i>	469
<i>Personalized management B cell lymphomas</i>	469
<i>Personalized vaccine for follicular lymphoma</i>	470
<i>Pharmacoproteomics approach to diffuse large B cell lymphoma</i>	470
<i>Companion diagnostic for treatment of lymphoma with Adcentris™</i>	471
Personalized management of gastrointestinal tumors	471
<i>Personalized management of esophageal cancer</i>	471
<i>Personalized management of gastric cancer</i>	472
<i>Personalized management of gastrointestinal stromal tumors</i>	473
Personalized management of colorectal cancer	473
<i>Developing personalized therapies for CRC</i>	474
<i>Molecular diagnosis for guiding personalized management of CRC</i>	474
<i>Role of staging of CRC in prognosis and management decisions</i>	475
<i>Role of biomarkers in personalized management of CRC</i>	476
<i>Role of miRNA modeling in personalized management of CRC</i>	478
<i>Resistance to targeted EGFR blockade in CRC</i>	478
<i>Sequencing for personalized management of colorectal cancer</i>	479
<i>Systems biology approach to drug resistance in colorectal cancer</i>	479
Personalized management of liver cancer.....	480
<i>Prognosis of HCC in relation to management</i>	480
<i>Prediction of recurrence of hepatocellular carcinoma</i>	481
<i>Prediction of survival of patients with fibrolamellar HCC</i>	481
Personalized management of lung cancer.....	482
<i>ALK inhibitors for personalized management of NSCLC</i>	482

<i>Bronchial genomic classifier for diagnostic of lung cancer</i>	483
<i>Companion diagnosis for NSCLC therapeutics</i>	483
<i>Copy number variations as a diagnostic tool for lung cancer</i>	483
<i>EGFR tyrosine kinase inhibitor treatment</i>	483
<i>Development of resistance to EGFR inhibitors</i>	485
<i>Molecular subtyping of lung cancer</i>	486
<i>miRNA classifiers as diagnostic/prognostic tools in lung cancer</i>	486
<i>Personalized therapy of NSCLC based on KIF5B/RET fusion oncogene</i>	487
<i>Predicting response of NSCLC to platinum-based therapy</i>	487
<i>Proteomics for discovery of metabolic biomarkers of lung cancer</i>	487
<i>Role of a new classification system in the management of lung cancer</i>	487
<i>Selecting therapy of cancer arising from respiratory papillomatosis</i>	488
<i>Sequencing the genomes of SCLC</i>	488
<i>Testing for response to chemotherapy in lung cancer</i>	488
<i>Testing for prognosis of lung cancer</i>	489
<i>Testing for recurrence of lung cancer</i>	489
Personalized management of malignant melanoma	490
<i>Inhibitors of BRAF mutation for metastatic melanoma</i>	490
<i>Management of drug-resistant metastatic melanoma</i>	491
<i>Vaccine for malignant melanoma based on heat shock protein</i>	491
Personalized management of endocrine tumors	492
<i>Adosterone producing tumors</i>	492
<i>Neuroendocrine tumors</i>	492
<i>Parathyroid tumors</i>	493
<i>Personalized management of pheochromocytoma and paraganglioma</i>	494
Personalized management of osteosarcoma	494
Personalized management of pancreatic cancer	495
<i>Biomarkers of pancreatic cancer</i>	495
<i>Histone modifications predict treatment response in pancreatic cancer</i>	496
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i>	496
Personalized management of prostate cancer	497
<i>Assessing susceptibility to prostate cancer by genotyping</i>	497
<i>Diagnostics for guiding therapy of prostate cancer</i>	497
<i>Detection of prostate cancer metastases</i>	498
<i>Early detection of cancer recurrence and guiding treatment</i>	498
<i>Effects of lifestyle changes shown by gene expression studies</i>	499
<i>Epigenetics-based assays for guiding decision to biopsy prostate</i>	499
<i>Genomic patterns of aggressiveness of prostate cancer</i>	499
<i>Personalized peptide vaccine for prostate cancer</i>	500
<i>Selection of prostate cancer patients responsive to rucaparib therapy</i>	500
Personalized management of thyroid cancer	500
Future of cancer therapy	501
Challenges for developing personalized cancer therapies	501
Personalizing anticancer drug combinations	502
Cancer Genome Atlas	502
Cancer Moonshot	503
<i>Blood Profiling Atlas</i>	503
<i>NCI collaborations</i>	503
COLTHERES consortium	504
Computer and imaging technologies for personalizing cancer treatment	504
Genomic Cancer Care Alliance	505
Integrated genome-wide analysis of cancer for personalized therapy	505
International Cancer Genome Consortium	505
National Cancer Institute of US	507
<i>Catalog of cancer genes for personalized therapy</i>	507
<i>NCI-designated Comprehensive Cancer Centers</i>	508
<i>Role of NCI Genomic Data Commons in personalized cancer therapy</i>	508
Precision Oncology Decision Support at MD Anderson Cancer Center	509
PREDICT Consortium	510
Quebec Clinical Research Organization in Cancer	510
The San Antonio 1000 Cancer Genomes Project	510
Companies involved in developing personalized oncology	511
11. Development of Personalized Medicine	514
Introduction	514
Non-genomic factors in the development of personalized medicine	514
Personalized medicine based on circadian rhythms	514
Cytomics as a basis for personalized medicine	516
Intestinal microflora	516
<i>Gut microbiome compared to human genome</i>	516
<i>Metabolic interactions of the host and the intestinal microflora</i>	517

Role of drug delivery in personalized medicine.....	517
Personalized approach to clinical trials.....	517
<i>Adaptive clinical trials</i>	518
<i>Bayesian approach in biomarker-based clinical trials</i>	519
<i>Clinical trials of therapeutics and companion diagnostics</i>	520
<i>Clinical trials on selected subpopulations of patients</i>	520
<i>Clinical trials networks</i>	520
<i>Creative clinical trial design</i>	521
<i>Individualizing risks and benefits in clinical trials</i>	521
Players in the development of personalized medicine.....	522
Personalized Medicine Coalition.....	522
Role of pharmaceutical industry.....	523
<i>Repositioning of drugs for personalized medicine</i>	524
<i>Discovery of personalized medicines</i>	524
<i>Personalized drug delivery</i>	525
<i>Production and distribution of personalized medicines</i>	525
Role of biotechnology companies.....	526
Role of life sciences industries.....	526
Role of biomedical engineering in wearable devices for personalized healthcare.....	526
Role of molecular imaging in personalized medicine.....	527
<i>Molecular imaging for personalized drug development in oncology</i>	527
<i>Molecular imaging and CNS drug development</i>	529
<i>Companies involved in molecular imaging</i>	530
Role of the clinical laboratories.....	530
Role of the US government in personalized medicine.....	531
<i>Precision Medicine Initiative</i>	532
<i>Department of Health and Human Services and personalized medicine</i>	534
<i>Agency for Healthcare Research and Quality</i>	535
<i>Comparative effectiveness research</i>	536
Role of the US Government agencies in personalized medicine.....	537
<i>NIH's Roadmap Initiative for Medical Research</i>	537
<i>NIH and personalized medicine</i>	538
<i>NIH collaboration with the FDA</i>	538
<i>NIH and Genetic Testing Registry</i>	538
<i>National Human Genome Research Institute</i>	539
<i>National Institute of General Medical Sciences</i>	539
<i>National Institute of Standards and Technology</i>	541
<i>Role of the Centers for Disease Control</i>	541
Role of academic institutions and health centers in the US.....	542
<i>Baylor College of Medicine</i>	542
<i>California Initiative to Advance Precision Medicine</i>	542
<i>Children's Hospital of Los Angeles</i>	543
<i>Clinical Proteomics Program of NCI & FDA</i>	543
<i>Coriell Personalized Medicine Collaborative™</i>	543
<i>Delaware Valley Personalized Medicine Project</i>	544
<i>Duke University Medical Center and genomic medicine</i>	544
<i>Evaluation of genetic tests and genomic applications</i>	545
<i>Indiana University Institute for Personalized Medicine</i>	545
<i>Inova Center for Personalized Health</i>	546
<i>Institute of Medicine's role in personalized medicine</i>	546
<i>Jackson Laboratory for Genomic Medicine</i>	546
<i>Johns Hopkins Center for Personalized Cancer Medicine Research</i>	547
<i>Mayo Clinic's Centers for Individualized Medicine</i>	547
<i>Mt. Sinai Medical Center's Personalized Medicine Research Program</i>	548
<i>North Shore University's Center for Personalized Medicine</i>	548
<i>P4 Medicine Institute</i>	549
<i>Personalized Medicine Partnership of Florida</i>	549
<i>Personalized oncology at Massachusetts General Hospital</i>	549
<i>Personalized oncology at Oregon Health & Science University</i>	550
<i>Pharmacogenetics Research Network and Knowledge Base</i>	550
<i>Southeast Nebraska Cancer Center's Personalized Medicine Network</i>	551
<i>Spectrum Health Center for personalized cancer care</i>	551
<i>Stanford Center for Genomics and Personalized Medicine</i>	551
<i>UAB-HudsonAlpha Center for Genomic Medicine</i>	551
<i>University of Colorado's Center for Personalized Medicine</i>	552
<i>UNC Institute for Pharmacogenomics and Individualized Therapy</i>	552
<i>Weill Cornell's Englander Institute for Precision Medicine</i>	553
<i>Wisconsin Genomics Initiative</i>	553
Role of academic collaborations with companies.....	553
<i>New York Genome Center</i>	553
Role of healthcare organizations.....	554

Role of the medical profession	554
<i>The American Medical Association and personalized medicine</i>	554
<i>Education of the physicians</i>	555
<i>Off-label prescribing and personalized medicine</i>	555
<i>Medical education</i>	556
Role of patients	556
<i>Monitoring of patient compliance with therapy</i>	556
<i>Public attitude towards personalized medicine</i>	556
<i>Patient participation in disease management decisions</i>	557
<i>Patient engagement in clinical trials of personalized medicine</i>	558
Role of genetic banking systems and databases	559
Role of biobanks in development of personalized medicine	559
UK Biobank	559
Biobanking and development of personalized medicine in EU	560
<i>BBMRI-ERIC</i>	560
CARTaGENE for biobanks in Canada	560
Personalized medicine based on PhysioGenomics™ technology	560
Role of bioinformatics in development of personalized medicine	561
Artificial intelligence in personalized medicine	562
Biosensing and wearable devices for monitoring of health	563
Biosimulation techniques for developing personalized medicine	563
Digitalized medicine	563
Genomic data analysis	564
Exploration of disease-gene relationship	564
Health information management	564
Electronic health records	565
<i>Analysis of -omic and EHR data of the patient</i>	565
<i>Cost of EHR and savings on healthcare expenses in the US</i>	566
<i>EHRs and genome-wide studies</i>	566
<i>Linking patient medical records and genetic information</i>	566
<i>Management of personal genomic data</i>	567
<i>Use of EHRs for improving safety of new medicines</i>	567
<i>Use of EHRs for genetic research</i>	567
<i>Use of EHRs for personalized drug discovery and development</i>	568
Personalized prognosis of disease	568
Integration of technologies for personalized medicine	569
Global scope of personalized medicine	569
<i>Global Alliance for Genomics and Health</i>	569
Personalized medicine in Canada	570
<i>Personalized medicine at Ontario Institute for Cancer Research</i>	570
<i>Personalized Medicine Partnership for Cancer in Quebec</i>	572
<i>Quebec Center of Excellence in Personalized Medicine</i>	572
Personalized medicine in the EU	572
<i>European Personalized Medicine Diagnostics Association</i>	573
<i>UK National Health Service and medical genetics</i>	573
<i>UK's Precision Medicine Catapult</i>	574
<i>Personalized medicine in Germany</i>	574
<i>Ubiquitous Pharmacogenomics project</i>	575
Personalized medicine in Israel	575
Personalized medicine in Japan	576
Personalized medicine in the developing countries	576
<i>Personalized medicine in the Middle East</i>	577
<i>Personalized medicine in China</i>	577
Advantages of personalized medicine	578
Limitations of personalized medicine	578
Non-genomic factors in response to drugs	579
Incidental findings in genetic screening and clinical sequencing	579
Future of personalized medicine	581
Ongoing genomic projects	581
<i>Understanding the genetic basis of diseases</i>	581
<i>Personal Genome Project</i>	581
<i>Genome-wide association studies</i>	582
<i>The 1000 Genomes Project</i>	583
<i>Genomics of aging in a genetically homogeneous population</i>	583
Translational science and personalized medicine	584
<i>Translation of genomic research into genetic testing for healthcare</i>	584
<i>Long-term behavioral effects of personal genetic testing</i>	585
Personalized predictive medicine	585
Connected health and personalized medicine	586
Opportunities and challenges	586
<i>Comparative-effectiveness research and personalized medicine</i>	586

<i>Genetic testing and concerns about equality of healthcare</i>	586
<i>Initiative for delivery for precision medicine</i>	587
<i>IGNITE network – implementing personalized medicine in clinical care</i>	587
<i>Prospects and limitations of genetic testing</i>	588
<i>Personalized medicine and public health</i>	589
<i>Pharmacotyping</i>	589
<i>Medicine in the year 2023</i>	590
Concluding remarks about the future of personalized medicine	590
12. Ethical, Legal and Regulatory Aspects of Personalized Medicine	594
Introduction to ethical issues	594
Ethical issues of pharmacogenetics	594
Ethical aspects of genetic information	594
<i>Ethical issues of whole genome analysis</i>	594
<i>Ethical aspects of direct-to-consumer genetic services</i>	595
<i>Privacy issues in personalized medicine</i>	596
<i>Genetic Information Nondiscrimination Act in the US</i>	597
<i>UNESCO and ethical aspects of personalized medicine</i>	597
Genotype-specific clinical trials	597
Social issues in personalized medicine	598
<i>Race and personalized medicine</i>	598
Legal issues of personalized medicine	600
Gene patents and personalized medicine.....	601
Regulatory aspects	601
FDA and personalized medicine.....	602
<i>FDA oversight of NGS for personalized medicine</i>	602
FDA and molecular diagnostics in relation to personalized medicine.....	603
<i>CLSI guideline for the use of RNA controls in gene expression assays</i>	603
<i>Evaluation of companion diagnostics/therapeutic</i>	604
<i>FDA oversight of laboratory developed tests</i>	605
<i>FDA regulation of multivariate index assays</i>	606
<i>FDA guidelines for the role of IVD in personalized medicine</i>	607
<i>IVD device and drug co-development</i>	608
Regulatory aspects of pharmacogenetics.....	609
Regulation of direct-to-consumer genetic testing	609
<i>Need for regulatory oversight of DTC</i>	609
FDA and pharmacogenomics	612
<i>FDA guidance for pharmacogenomic data submissions</i>	613
<i>Joint guidelines of the FDA and EU regulators for pharmacogenomics</i>	613
<i>Pharmacogenomic/pharmacogenetic information in drug labels</i>	614
<i>FDA guidelines for pharmacogenomics-based dosing</i>	614
<i>FDA and validation of biomarkers</i>	615
FDA and predictive medicine	616
13. Commercial Aspects of Personalized Medicine	618
Introduction	618
Perceived financial concerns.....	618
Personalized medicine and orphan drug syndrome	618
Commercial aspects of pharmacogenomics	618
Cost of DNA testing	618
Cost of sequencing the human genome	619
Cost of genotyping	621
Cost of pharmacogenomics-based clinical trials.....	622
Business development of pharmacogenomic companies	622
Cost of personalized healthcare	622
The rising healthcare costs in the US.....	622
<i>Genetic testing and cost of healthcare</i>	623
Reducing healthcare costs by combining diagnostics with therapeutics	624
<i>Cost-effectiveness of pharmacogenetic testing</i>	624
<i>Cost-effectiveness of CYP genotyping-based pharmacotherapy</i>	625
<i>Cost effectiveness of HIV genotyping in treatment of AIDS</i>	625
<i>Cost-effectiveness of warfarin pharmacogenomics</i>	626
<i>Cost-benefit analysis of KRAS and BRAF screening in CRC</i>	626
<i>Lowering the high costs of cancer chemotherapy</i>	626
Overall impact of personalized medicine on healthcare	627
Drivers for the development of personalized medicine	627
Evolution of medicine as a driver for personalized therapy markets	628
Collaboration between the industry and the academia	628
Personalized medicine and drug markets	629
Segmentation of therapeutic drug markets.....	629
Reasons for increase of market values of personalized medicines.....	629

Growth of markets relevant to personalized medicine	630
<i>Biochips for diagnosis</i>	630
<i>Pharmacogenetics</i>	631
<i>Pharmacogenomics</i>	631
<i>Pharmacoproteomics</i>	631
<i>Point-of-Care</i>	631
<i>SNP market</i>	631
Markets for personalized medicines according to therapeutic areas	631
<i>Market for personalized cancer therapy</i>	632
Markets for personalized medicines according to geographical regions	632
Market opportunities for personalization of medicine	632
Impact of personalized medicine on other industries	633
Strategies for developing and marketing personalized medicine	634
<i>Education of the public</i>	634
<i>Role of the Internet in development of personalized medicine</i>	635
<i>Marketing companion diagnostics for personalized medicine</i>	635

14. References..... 638

Tables

Table 1-1: Selected terms relevant to the concept of personalized medicine.....	28
Table 1-2: Landmarks in the historical development of personalized medicine	29
Table 1-3: Genetic variations in the human genome.....	35
Table 1-4: Examples of systems medicine-based diagnostic/therapeutic approaches	53
Table 2-1: Molecular diagnostic technologies used for personalized medicine	58
Table 2-2: Applications of biochip technology relevant to personalized medicine	80
Table 2-3: Companies developing haplotyping technology	95
Table 2-4: Technologies for SNP analysis	95
Table 2-5: A sampling of companies involved in technologies for SNP genotyping	101
Table 2-6: Comparison of proteomic and genomic approaches in personalized medicine	107
Table 2-7: Selected methods for gene expression profiling	113
Table 2-8: A selection of companies with gene expression technologies	118
Table 2-9: Drugs requiring biomarker/companion diagnostic information in the label	120
Table 2-10: Companies involved in companion diagnostics.....	121
Table 2-11: Applications of point-of-care diagnosis	123
Table 2-12: Companies developing point-of-care diagnostic tests	124
Table 2-13: Companies offering genetic screening tests directly to consumers	128
Table 3-1: Pharmacogenetic vs. pharmacogenomic studies	135
Table 3-2: Enzymes relevant to drug metabolism	137
Table 3-3: Examples of mutation of the enzyme CYP450	138
Table 3-4: Frequency distribution of drugs metabolized by major isoforms of CYP450.	138
Table 3-5: Commonly prescribed medications, which are metabolized by CYP2D6.....	138
Table 3-6: Polymorphisms in drug target genes that can influence drug response	144
Table 3-7: Effect of genetic polymorphisms on disease response to drugs	145
Table 3-8: Examples of genetically determined adverse reactions to drugs	148
Table 3-9: Examples of genotyping and phenotyping in some diseases	156
Table 3-10: Companies with novel molecular toxicology technology	159
Table 3-11: Pharmacogenomic biomarkers in drug labeling	162
Table 4-1: Role of pharmacogenomics in variable therapy targets.....	170
Table 4-2: Role of pharmacogenomics in clinical trials	173
Table 4-3: Examples of pharmacogenomics-based clinical studies	174
Table 4-4: Tumor suppressor genes, their chromosomal location, function and associated tumors.	177
Table 4-5: Gene polymorphisms relevant to cardiovascular disease management	178
Table 4-6: Companies involved in cardiovascular genomics.....	180
Table 4-7: SNPs in genes implicated in response of bipolar disorder to lithium.....	182
Table 4-8: A sampling of companies involved in neuropharmacogenomics	183
Table 5-1: Applications of pharmacoproteomic biomarkers in personalized medicine	191
Table 8-1: Companies involved in personalized nutrition.....	213
Table 9-1: Important therapeutic areas for personalized medicine	216
Table 9-2: Enzymes that metabolize antipsychotics.....	232
Table 9-3: Enzymes that metabolize antidepressants	233
Table 9-4: Biomarkers of response to antidepressant treatment	234
Table 9-5: Brain imaging for diagnosis of neurodegenerative parkinsonism	240
Table 9-6: Biomarkers of epilepsy.....	244
Table 9-7: Influence of gene polymorphisms on efficacy of antiepileptic drugs.....	248
Table 9-8: Biomarkers of stroke	254
Table 9-9: Role of cell therapy in management of stroke according to stage.....	258
Table 9-10: Gene expression as biomarker of response to IFN- β in multiple sclerosis	262

Table 9-11: Biomarkers of traumatic brain injury	264
Table 9-12: P450 isoforms in the metabolism of drugs used in the management of pain	268
Table 9-13: Personalized management of neuropathic pain based on mechanism	272
Table 9-14: Genes that cause cardiovascular diseases.....	274
Table 9-15: Classification of diabetes into 5 clusters	321
Table 9-16: Genetic influences on pharmacotherapy of alcoholism	332
Table 10-1: Factors that drive the development of personalized therapy in cancer	342
Table 10-2: Impact of molecular diagnostics on the management of cancer	348
Table 10-3: FDA-approved companion diagnostics for cancer	351
Table 10-4: Marketed anticancer personalized medicines	375
Table 10-5: Monoclonal antibodies for cancer approved by the FDA	376
Table 10-6: Clinical trials of personalized cancer vaccines.....	392
Table 10-7: Future developments in oncology relevant to personalized management	501
Table 10-8: Selected companies involved in developing personalized oncology	511
Table 11-1: Bayesian versus frequentist approaches in clinical trials	519
Table 11-2: Players in the development of personalized medicine	522
Table 11-3: Members of the Personalized Medicine Coalition	523
Table 11-4: Biobanks relevant to personalized medicine	559
Table 11-5: Role of bioinformatics in the development of personalized medicine.....	561
Table 11-6: Advantages of personalized medicine for the biopharmaceutical industry.....	578
Table 11-7: Advantages of personalized medicine for the patients	578
Table 11-8: Advantage of personalized medicine for the physicians.....	578
Table 11-9: Advantage of personalized medicine for the healthcare providers	578
Table 11-10: Limitations of personalized medicine	578
Table 11-11: Recommendations of the Association for Molecular Pathology on incidental findings	580
Table 11-12: Methods of translational science that are relevant to personalized medicine.....	584
Table 11-13: Companies involved in predictive healthcare	585
Table 11-14: Delivery for precision medicine.....	587
Table 12-1: Drugs with genetic information in their labels.....	614
Table 13-1: Drivers for the development of personalized medicine.....	627
Table 13-2: Growth of markets relevant to personalized medicine 2017-2027	630
Table 13-3: Markets for personalized medicine according to therapeutic area 2017-2027.....	632
Table 13-4: Markets for personalized medicine in major regions 2017-2027.....	632
Table 13-5: Lack of efficacy in current therapy	633
Table 13-6: Impact of personalized medicine on other industries	633
Table 13-7: Strategies to develop personalized medicine	634
Table 13-8: Role of the Internet in development of personalized medicine	635

Figures

Figure 1-1: Relation of personalized medicine to other technologies	45
Figure 1-2: Relation of systems pharmacology to personalized medicine.....	52
Figure 2-1: Role of sequencing in personalized medicine.....	76
Figure 2-2: Role of biochip/microarray technology in personalized medicine	80
Figure 2-3: Application of biochips/microarrays in personalized therapy.....	81
Figure 2-4: Affymetrix GeneChip technology	82
Figure 2-5: Role of CYP450 genotyping in development of personalized medicine	83
Figure 2-6: Role of SNPs in personalized medicine	91
Figure 2-7: A scheme of integrated healthcare and personalized medicine	130
Figure 3-1: Pharmacogenetics as a link between genotype and phenotype	134
Figure 3-2: Role of pharmacogenetic technologies in personalized medicine	135
Figure 4-1: Impact of new technologies at various stages of the drug discovery process.....	172
Figure 4-2: Steps in the application of pharmacogenomics in clinical trials	174
Figure 7-1: Role RNAi in development of personalized medicine.....	204
Figure 8-1: A scheme of various factors in personalized nutrition.....	208
Figure 9-1: Workflow of genotypic resistance analysis for personalized HIV therapy	223
Figure 9-2: Components of multimodal therapy for neurological disorders.....	238
Figure 9-3: Scheme of iPSCs use for personalized cell therapy of Parkinson disease	241
Figure 9-4: An algorithm for personalized management of epilepsy.....	244
Figure 9-5: Algorithm for anticoagulant therapy to prevent stroke in atrial fibrillation.....	256
Figure 9-6: Spot sign of extravasation and expansion of intracerebral hematoma	257
Figure 9-7: A scheme of personalized therapy of multiple sclerosis	260
Figure 9-8: Personalized targeting of therapeutic agents to lesions of multiple sclerosis.....	264
Figure 9-9: Essential components of personalized management of pain	266
Figure 9-10: Genetic and non-genetic factors affecting efficacy and side effects of opioids	269
Figure 9-11: An algorithm for personalized management of pain	271
Figure 9-12: Assessment of stable coronary artery disease	280
Figure 9-13: Flow chart of personalized approach to management of atrial fibrillation	286
Figure 9-14: A scheme of personalized approach to management of hypertension	296
Figure 9-15: Basis of personalized approach to idiopathic pulmonary fibrosis (IPF)	311

Figure 9-16: Steps in growing a new heart in vitro for transplantation	327
Figure 10-1: Relationships of technologies for personalized management of cancer.....	348
Figure 10-2: Integration of technologies for personalized prevention of cancer	362
Figure 10-3: CRISPR-Cas9 in personalized cancer gene therapy	397
Figure 10-4: Use of LC-MS/MS to select appropriate targeted therapy for cancer	402
Figure 10-5: Personalized cancer therapy based on targeted proteomics.....	403
Figure 10-6: Applications of NCI Genomic Data Commons	508
Figure 10-7: Workflow for development of gene pages for personalized cancer therapy	510
Figure 11-1: Integration of technologies for the development of personalized medicine	569
Figure 12-1: Strategy for drug and test co-development.....	608
Figure 13-1: Cost of sequencing per genome	621
Figure 13-2: Evolution of personalized medicine as a market driver	628